Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.86 USD

198.86
4,683,324

+2.56 (1.30%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $198.55 -0.31 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

If You Invested $1000 in AbbVie a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs

by Kinjel Shah

FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.

Zacks Equity Research

J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease

by Zacks Equity Research

J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.

Zacks Equity Research

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Zacks Equity Research

Here's Why AbbVie (ABBV) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.

Zacks Equity Research

AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the closing of the recent trading day, AbbVie (ABBV) stood at $171.36, denoting a +0.99% change from the preceding trading day.

Zacks Equity Research

Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study

by Zacks Equity Research

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails

by Kinjel Shah

An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.

Zacks Equity Research

AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate

by Zacks Equity Research

AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.

Zacks Equity Research

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DHS

Zacks Equity Research

AbbVie (ABBV) Laps the Stock Market: Here's Why

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $170.46, moving +0.61% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval

by Kinjel Shah

Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.

Zacks Equity Research

AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal

by Zacks Equity Research

Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.

Zacks Equity Research

AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

by Zacks Equity Research

The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.

Zacks Equity Research

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the most recent trading session, AbbVie (ABBV) closed at $160.19, indicating a -0.65% shift from the previous trading day.

Zacks Equity Research

AbbVie (ABBV) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Zacks Equity Research

AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

by Zacks Equity Research

AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.

Zacks Equity Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Zacks Equity Research

AbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal

by Zacks Equity Research

Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.

Zacks Equity Research

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHD

Zacks Equity Research

Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?

by Zacks Equity Research

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

Zacks Equity Research

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.